8 Oversold Stocks to Buy Right Now
On June 1, Tom Lee, Fundstrat Managing Partner & Head of Research, and Fundstrat Capital CIO, appeared on CNBC's 'Squawk Box' to discuss the latest market trends.
Maze Therapeutics Inc. (MAZE)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 3,477,562 | $103,805,226 | -19% | 1.7% |
| 2. | Paradigm Biocapital Advisors Senai Asefaw | 2,744,399 | $81,920,310 | 1.67% | |
| 3. | A16z Capital Management Marc Andreessen And Ben Horowitz | 1,702,225 | $50,811,416 | 3.94% | |
| 4. | Logos Capital Arsani William | 1,235,000 | $36,864,750 | +30% | 1.84% |
| 5. | Adage Capital Management Phill Gross And Robert Atchinson | 1,178,000 | $35,163,300 | 0.05% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $30.34 | 1,200 | $36,404.28 | 0 | 2026-07-01 | Filing | |
| $29.87 | 13,409 | $400,459.79 | 1,200 | 2026-07-01 | Filing | |
| $30.44 | 1,597 | $48,606.13 | 287,171 | 2026-07-01 | Filing | |
| $29.95 | 30,311 | $907,920.54 | 288,768 | 2026-07-01 | Filing | |
| $29.98 | 2,593 | $77,726.21 | 23,337 | 2026-07-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,370 | $428,801 | 0.01% | |
| 2. | 9,630 | $287,359 | 0.02% | |
| 3. | 170 | $5,073 | 0% | |
| 4. | 112 | $3,342 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
10 Oversold Small Cap Stocks to Buy Now
In this article, we will take a look at some of the most oversold small-cap stocks that currently offer attractive upside to investors. On April 18, stocks in the U.S.
Truist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant Impact
TheFly reported on April 14 that Truist Securities maintained its Buy rating on MAZE while reducing its price target from $68 to $64.
8 Oversold Biotech Stocks to Invest In Now
On February 5, J.P. Morgan revealed major themes that are expected to affect healthcare in 2026, emphasizing a resurgence of interest in the biopharma sector.
8 Most Oversold Strong Buy-Rated Stocks to Invest In
Oversold stocks are getting a fresh look in 2026, but not simply because they are down.
Maze Therapeutics, Inc. (MAZE): A Bull Case Theory
We came across a bullish thesis on Maze Therapeutics, Inc. on deep market scan subreddit by retroviber. In this article, we will summarize the bulls’ thesis on MAZE.